Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans
- Conditions
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 12
- Registration Number
- NCT01280006
- Locations
- 🇨🇦
The Laboratory of Human Cerebrovascular Physiology, HMRB 209 & HMRB 230, University of Calgary, Calgary, Alberta, Canada
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
- Conditions
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT01258868
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 27
- Registration Number
- NCT01220973
- Locations
- 🇺🇸
Cooper Hospital, Camden, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT01186887
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01158534
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-06-24
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 2527
- Registration Number
- NCT01150045
- Locations
- 🇺🇸
Mount Carmel Hospital East, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT01143545
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation
- Conditions
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 20
- Registration Number
- NCT01129245
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 255
- Registration Number
- NCT01062113
- Locations
- 🇯🇵
Kumamoto Medical Center, Kumamoto-shi, Kumamoto, Japan
🇯🇵Jyuzen General Hospital, Niihama-shi, Ehime, Japan
🇯🇵Maruko Central General Hospital, Ueda-shi, Nagano, Japan
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-01-01
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 313
- Registration Number
- NCT01041781
- Locations
- 🇺🇸
Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States
🇺🇸Toledo Clinic Cancers Centers - Maumee, Maumee, Ohio, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.